Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

92992

	registered interest
	date	13/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department provides to clinical commissioning groups about commissioning services on treatments from hospitals (a) in Scotland and (b) outside their own area.
	tabling member constituency	Berwick-upon-Tweed
	tabling member printed	Sir Alan Beith
	uin	210196
	answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>Clinical commissioning groups’ (CCGs) commissioning responsibilities are set out in the NHS Act 2006, The National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012 (SI 2012/2996) and The National Health Service (Clinical Commissioning Groups— Disapplication of Responsibility) Regulations 2013 (SI 2013/350), as amended.</p><p> </p><p> </p><p> </p><p>NHS England have published the document ‘Who Pays? Determining responsibility for payments to providers’ which provides guidance for CCGs on commissioning services from hospitals in Scotland and outside their own area.</p><p> </p><p> </p><p> </p><p>A copy is attached.</p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 16/10/2014 15:10:39 answering member 1439 label Biography information for Norman Lamb attachment 1 file name who-pays.pdf title Who Pays? NHS England August 2013
	tabling member	513 label Biography information for Lord Beith

48229

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of the role independent pharmacies play in relieving pressures on other health and welfare services; and what steps he has taken to disseminate best practice.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	196239
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>Pharmacy already plays a vital role in supporting the health of people in their local communities, providing high quality care and support, improving people's health and reducing health inequalities. However, as we move to more integrated care, there is real potential for pharmacists and their teams to play an even greater role in the future, particularly in keeping people healthy, supporting those with long term conditions and helping make sure patients and the National Health Service get the best use from medicines.</p><p> </p><p>NHS England's public consultation, <em>Improving care through community pharmacy –</em> <em>a call to action</em>, which closed on 18 March, has provided an important opportunity to explore the contribution community pharmacists and their teams can make. This will inform a strategic framework for commissioning wider primary care services in the autumn. A copy of the consultation document is at:</p><p> </p><p>www.england.nhs.uk/ourwork/qual-clin-lead/calltoaction/pharm-cta/</p><p> </p><p>In the meantime, NHS England's <em>The earlier, the better</em> campaign, launched in January 2014, specifically sought to raise the profile of community pharmacy with the public, to increase the number of people accessing community pharmacy services when they have a minor ailment and reduce pressures on other parts of the NHS.</p><p> </p><p>On 14 April, the Department and NHS England published <em>Transforming Primary Care - Safe, proactive, personalised care for those who need it most</em>. This sets out plans for more proactive, personalised and joined up care, part of which is harnessing the potential of pharmacists. This recognises the vital role that pharmacists have in optimising medicines use, helping to prevent avoidable hospital admissions and supporting people to manage their own care. A copy has been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 196241 question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name 196239_and_196241_-_Library_document[1].pdf title Transforming Primary Care document
	tabling member	4006 label Biography information for Dr Matthew Offord

48241

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he has taken to increase public understanding of the services offered by independent pharmacies.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	196241
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>Pharmacy already plays a vital role in supporting the health of people in their local communities, providing high quality care and support, improving people's health and reducing health inequalities. However, as we move to more integrated care, there is real potential for pharmacists and their teams to play an even greater role in the future, particularly in keeping people healthy, supporting those with long term conditions and helping make sure patients and the National Health Service get the best use from medicines.</p><p> </p><p>NHS England's public consultation, <em>Improving care through community pharmacy –</em> <em>a call to action</em>, which closed on 18 March, has provided an important opportunity to explore the contribution community pharmacists and their teams can make. This will inform a strategic framework for commissioning wider primary care services in the autumn. A copy of the consultation document is at:</p><p> </p><p>www.england.nhs.uk/ourwork/qual-clin-lead/calltoaction/pharm-cta/</p><p> </p><p>In the meantime, NHS England's <em>The earlier, the better</em> campaign, launched in January 2014, specifically sought to raise the profile of community pharmacy with the public, to increase the number of people accessing community pharmacy services when they have a minor ailment and reduce pressures on other parts of the NHS.</p><p> </p><p>On 14 April, the Department and NHS England published <em>Transforming Primary Care - Safe, proactive, personalised care for those who need it most</em>. This sets out plans for more proactive, personalised and joined up care, part of which is harnessing the potential of pharmacists. This recognises the vital role that pharmacists have in optimising medicines use, helping to prevent avoidable hospital admissions and supporting people to manage their own care. A copy has been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 196239 question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name 196239_and_196241_-_Library_document[1].pdf title Transforming Primary Care document
	tabling member	4006 label Biography information for Dr Matthew Offord

50398

	registered interest
	date	08/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the findings of the recent Global Forum on Incontinence into improving health and social care in incontinence.
	tabling member constituency	Heywood and Middleton
	tabling member printed	Jim Dobbin
	uin	198200
	answer	answer is ministerial correction date of answer 13/05/2014 answer text <p>No assessment has been made of the findings of the recent Global Forum on Incontinence (GFI) into improving health and social care in incontinence. However, we applaud the work of the GFI and the work it is doing to improve the health and social care provisions for incontinence, giving patients and care givers a better quality of life.</p><p> </p><p>Responsibility for continence services sit with NHS England and clinical commissioning groups (CCG). CCGs are responsible for commissioning high quality continence services based on an assessment of local need and performance managing their providers in the delivery of high quality services.</p><p> </p><p>The Mandate to NHS England requires it to deliver continued improvements in relation to enhancing the quality of life for people with long-term conditions, including those suffering incontinence, across the five domains of the NHS Outcomes Framework. NHS England will be taking forward a major programme of work through the Primary Care Strategy; it has established a working group on continence care and will provide an update for the All Party Parliamentary Group for Continence Care on 24 June.</p><p> </p><p>To improve standards in continence care, the Department commissioned the National Institute for Health and Care Excellence (NICE) to develop clinical guidelines on the management of urinary incontinence in women (issued in 2006) and faecal incontinence in adults (issued in 2007), which are supported by commissioning tools to support CCGs. In February, NICE published a clinical Quality Standard on Faecal Incontinence, QS54, which describes high-priority areas for quality improvement in this area. NHS England continues to champion the use of Quality Standards with both commissioners and providers.</p><p> </p><p>We believe all patients have the right to be treated with dignity, respect and compassion.</p><p> </p><p>We recognise that continence can impact on every aspect of peoples' lives and that it often requires a joined approach from both health and social care services. That is why in April the Department published the policy paper, <em>Transforming Primary Care: safe proactive, personalised care for those who need it</em>, which focuses on improving and individualising the management of out of hospital care, directly supporting those with continence problems by creating more integrated health and social care services. This paper has been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 13/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198200 - Library Doc - Report.pdf title Transforming Primary Care
	tabling member	446 label Biography information for Jim Dobbin

65498

	registered interest
	date	02/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diversion of Individuals With mental Health Problems From the Criminal Justice System and Prison Review
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the recommendations of the Bradley Report five years on, published in June 2014.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	203857
	answer	answer is ministerial correction date of answer 08/07/2014 answer text <p>The Bradley Report from 2009 continues to inform policy discussions between Ministers and officials from the Department and across Government, and with NHS England and stakeholder members of the Bradley Report Group.</p><p> </p><p>We will consider the reports of progress and further recommendations in <em>The Bradley Report five years on </em>and consider with the Ministry of Justice, Home Office and NHS England any implications for future policy development.</p><p> </p><p>A copy of <em>The Bradley Report five years on </em>has been placed in the Library.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 08/07/2014 15:48:29 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ203857 - Lib Doc - Report.pdf title The Bradley Report five years on
	tabling member	4036 label Biography information for Luciana Berger

50483

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended for cancer treatment through either single or multiple technology appraisals in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198317
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198318 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50484

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the determined population size for each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has (a) recommended for cancer treatment and (b) recommended for cancer treatment under the end-of-life criteria in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198325
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198324 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50485

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has recommended for cancer treatments; and which such treatments and indications have been recommended under the end-of-life criteria in (a) 2012, (b) 2013 and (c) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198318
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50486

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended against in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198319
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50487

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has not recommended for cancer treatment in (a) 2012, (b) 2013 and (c) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198324
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech